Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Corporate Breaking News

Home : Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Nov 06 2019	Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a...


Source:https://www.prnewswire.com:443/news-releases/artios-pharma-md-anderson-and-shangpharma-announce-in-licensing-agreement-for-dna-damage-response-inhibitor-300952071.html

Related News
» The Knowledge Group Has Scheduled a Live Webcast on The Family and Medical Leave Act: Effective Compliance Practices You Should Know » ChipMOS REPORTS THIRD QUARTER 2019 RESULTS